[Note: Amitriptyline (brand name ElavilR) is a type of tricyclic antidepressant that has been tested in trials to determine its efficacy for improving sleep, pain and fatigue in non-depressed patients with Fibromyalgia - and has been prescribed off label for this purpose
The objective of this study was to assess the efficacy and safety of amitriptyline as a treatment of FM. A comprehensive computerized search in Medline (Pubmed), EMBASE and The Cochrane Library was performed. Randomized controlled trials (RCTs) comparing amitriptyline vs placebo in adult patients suffering from FM were identified, the methodological quality was assessed and the results of the main outcomes were evaluated.
Ten RCTs were identified. Large clinical variability and statistical heterogeneity precluded quantitative meta-analysis. Overall, the study quality was moderate to high.
Amitriptyline 25 mg/day (six RCTs) demonstrated a therapeutic response compared with placebo in the domains of pain, sleep, fatigue and overall patient and investigator impression.
This benefit was generally seen at 6-8 weeks of treatment but no effect was noted at 12 weeks.
Amitriptyline 50 mg/day (four RCTs) did not demonstrate a therapeutic effect compared with placebo.
Neither dose of amitriptyline had an effect on tender points count.
No clear statements on adverse events with amitriptyline can be made due to inconsistencies in data among the studies.
A definitive clinical recommendation regarding the efficacy of amitriptyline for FM symptoms cannot be made.
There is some evidence to support the short-term efficacy of amitriptyline 25 mg/day in FM.
There is no evidence to support the efficacy of amitriptyline at higher doses or for periods [more than] >8 weeks.
More stringent RCTs with longer follow-up periods are required to determine the long-term efficacy and safety of the amitriptyline and define its role in the multidisciplinary management of FM.
Source: Rheumatology (Oxford), Aug 12, 2008. [E-pub ahead of print] PMID: 18697829, by Nishishinya B, Urrútia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, Darko G. Iberoamerican Cochrane Center, Universitat Autònoma de Barcelona, Spain; Kovacs Foundation, Palma de Mallorca; CIBER Epidemiología y Salud Pública, Spain; Washington Hospital Center, Washington DC, USA; Hospital de la Vall d'Hebron, Barcelona, Spain. [E-mail: email@example.com]